Skip to main content

Advertisement

SpringerLink
Log in

Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Antitumor cytotoxicity of NK cells and T cells expressing NK-associated receptors is regulated by interaction between their cell surface killer immunoglobulin-like receptors (KIRs) and CD94/NKG2 heterodimers with MHC class I ligands on target cells. To test the hypothesis that KIR and/or HLA polymorphisms, and KIR/HLA combinations could contribute to the tumorigenesis, association studies were performed in 50 patients with malignant melanoma (MM) in different stages of disease and 54 controls. Our data showed that the frequency of inhibitory and activating KIR genes and KIR genotypes did not differ significantly between healthy individuals and melanoma patients. HLA haplotype distribution showed statistically significant increased frequencies of A*01-B*35-Cw*04 (0.069 vs 0.000; pc<0.05; OR=19.9), A*01-B*08-DRB1*03 (0.079 vs 0.019; pc<0.05; OR=4.5), and A*24-B*40-DRB1*11 (0.026 vs 0.000; pc<0.05; OR=7.1) in melanoma patients compared with healthy controls. Individuals homozygous for group 2 HLA-C ligands were less frequent in the patient group compared with the control cohort (12% vs 31.5%; p<0.017). In addition, we observed an increased frequency (88.0% vs 68.5%; p=0.017; OR=2.80) of KIR2DL2/2DL3 in combination with their group 1 HLA-C ligands, while the presence of these KIRs in the absence of the putative ligands was decreased (12.0% vs 31.5%; p=0.017) in the patient group. Furthermore, an increased frequency of activating KIR2DS1 in the absence of the putative HLA-CLys80 ligands was found in melanoma patients (16.0% vs 9.2%). In contrast, KIR2DS2 was absent in patients more often (38.0% vs 25.9%) when the presumptive HLA-CAsn80 ligands were present. A slightly higher incidence of KIR3DL1 in combination with the less effective Bw4Thr80 ligands was seen in patients with primary (20.8%) compared with metastatic (4.2%) disease. The data obtained in this study imply that there may not be a direct association between KIR gene content in the genome and the presence of malignant melanoma, or melanoma progression. However, some HLA haplotypes could be predisposing to MM in the Bulgarian population. Furthermore, distinct KIR/HLA ligand combinations may be relevant to the development of malignancy whereby inhibition overrides activation of NK cells and T cells expressing NK-associated receptors, which in turn might facilitate tumor escape and progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Joint Committee on Cancer (1992) Manual for staging of cancer, 4th edn. Lippincott, Philadelphia

  2. Bettinotti MP, Norris RD, Hackett JA, Thompson CO, Simonis TB, Stroncek D, Marincola FM (2000) Frequency of human leukocyte antigen-A24 alleles in patients with melanoma determined by human leukocyte antigen-A sequence-based typing. J Immunother 23:282

    Article  CAS  PubMed  Google Scholar 

  3. Biassoni R, Cantoni C, Falco M, Verdiani S, Bottino C, Vitale M, Conte R, Poggi A, Moretta A, Moretta L (1996) The human leucocyte antigen (HLA)-C-specific ‘activatory’ or ‘inhibitory’ natural killer cell receptors display highly homologous extracellular ddomains but differ in their transmembrane and intracytoplasmic portions. J Exp Med 183:645

    Article  CAS  PubMed  Google Scholar 

  4. Biswal BM, Kumar R, Julka PK, Sharma U, Vaidya MC (1998) HLA in breast cancer. Indian J Med Sci 52:177

    CAS  PubMed  Google Scholar 

  5. Boyington JC, Brooks AG, Sun PD (2001) Structure of killer cell immunoglobulin-like receptors and their recognition of the class I MHC molecules. Immunol Rev 181:66

    Article  CAS  PubMed  Google Scholar 

  6. Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M (1994) NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med 180:1235

    Article  CAS  PubMed  Google Scholar 

  7. Colonna M, Spies T, Strominger JL, Ciccone E, Moretta L, Pende D, Viale O (1992) Alloantigen recognition by two human natural killer cell clones is associated with HLA-C or a closely linked gene. Proc Natl Acad Sci U S A 89:7983

    CAS  PubMed  Google Scholar 

  8. Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL (1993) HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci U S A 90:12000

    CAS  PubMed  Google Scholar 

  9. Colonna M, Brooks EG, Falco M, Ferrara GB, Strominger JL (1993) Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 260:1121

    CAS  PubMed  Google Scholar 

  10. Crum KA, Logue SE, Curran MD, Middleton D (2000) Development of a PCR-SSOP approach capable of defining inhibitory receptor (KIR) gene sequence repertoire. Tissue Antigens 56:313

    Article  CAS  PubMed  Google Scholar 

  11. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M, Taniguch M (1997) Requirement for Vá14 NKT cells in IL-2-mediated rejection of tumours. Science 278:1623

    Article  CAS  PubMed  Google Scholar 

  12. Davidson EJ, Davidson JA, Sterling JC, Baldwin PJ, Kitchener HC, Stern PL (2003) Association between human leukocyte antigen polymorphism and human papillomavirus 16-positive vulval intraepithelial neoplasia in British women. Cancer Res 63(2):400

    CAS  PubMed  Google Scholar 

  13. Garrido F (1996) HLA and cancer. Tissue Antigens 47:361

    CAS  PubMed  Google Scholar 

  14. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993) Natural history of HLA expression during tumour development. Immunol Today 14:491

    Article  CAS  PubMed  Google Scholar 

  15. Garrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F (1995) HLA class I antigens in human tumors. Adv Cancer Res 67:155

    CAS  PubMed  Google Scholar 

  16. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 18:89

    Article  CAS  PubMed  Google Scholar 

  17. Gumperz JE, Litwin V, Philips JH, Lanier LL, Parham P (1995) The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 181:1133

    Article  CAS  PubMed  Google Scholar 

  18. Kageshita T, Naruse T, Hirai S et al (1997) Molecular genetics analysis of HLA class II alleles in Japanese patients with S melanoma. Tissue Antigens 49:466

    PubMed  Google Scholar 

  19. Kurosawa S, Harada M, Matsuzaki G, Shinomiya Y, Terao H, Kobayashi N, Nomoto K (1995) Early-appearing tumor-infiltrating natural killer cells play a crucial role in the generations of anti-tumour T lymphocytes. Immunology 85:338

    CAS  PubMed  Google Scholar 

  20. Lee JE, Reveille JD, Ross MI, Platsoucas CD (1994) HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int J Cancer 59:510

    CAS  PubMed  Google Scholar 

  21. Lee JE, Lu M, Mansfield PF, Platsoucas CD, Reveille JD, Ross MI (1996) Malignant melanoma: relationship of HLA class II gene DQB1*0301 to decreased recurrence in AJCC on cancer stage I or II. Cancer 78:758

    Article  CAS  PubMed  Google Scholar 

  22. Lombardi ML, Mercuro O, Pirozzi G, Ionna F, Lombari V, Mozzillo N, Manzo C (1998) Molecular analysis of HLA-DRB1 and HLA-DQB1 polymorphism in Italian melanoma patients. J Immunother 21:435

    CAS  PubMed  Google Scholar 

  23. Martin MP, Gao X, Lee J-H, Nelson GW, Detels R, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, Trowsdale J, Wilson M, O’Brien SJ, Carrington M (2002) Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31:429

    CAS  PubMed  Google Scholar 

  24. Martin MP, Nelson G, Lee J-H, Pellett F, Gao X, Wade J, Wilson MJ, Trowsdale J, Gladman D, Carrington M (2002) Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 169:2818

    CAS  PubMed  Google Scholar 

  25. Miller S, Dykes D, Polesky H (1988) A simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215

    CAS  PubMed  Google Scholar 

  26. Moodycliffe AM, Nghiem D, Clydesdale G, Ullrich SE (2000) Immune suppression and skin cancer development:regulation by NKT cells. Nat Immunol 1:521

    Article  CAS  PubMed  Google Scholar 

  27. Norman PJ, Stephens HAF, Verity DH, Chandanayingyong D, Vaughan RW (2001) Distribution of natural killer cell immunoglobulin-like receptor sequences in three ethnic groups. Immunogenetics 52:195

    Article  CAS  PubMed  Google Scholar 

  28. Parham P (2003) Immunogenetics of killer-cell immunoglobulin-like receptors. Tissue Antigens 62:194

    Article  CAS  PubMed  Google Scholar 

  29. Pende D, Accame L, Pareti L, Mazzocchi A, Moretta A, Parmiani G, Moretta L (1998) The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur J Immunol 28:2384

    Article  CAS  PubMed  Google Scholar 

  30. Porgador A, Mandelboim O, Restifo NP, Strominger JL (1997) Natural killer cell lines kill autologous β2 -microglobulin-deficient melanoma cells:implications for cancer immunotherapy. Proc Natl Acad Sci U S A 94:13140

    Article  CAS  PubMed  Google Scholar 

  31. Rajalingam R (2002) Diversity of NK cell receptors and their HLA class I ligands. ASHI Q 26:68

    Google Scholar 

  32. Rojo S, Wagtmann N, Long EO (1997) Binding of a soluble p70 killer cell inhibitory receptor to HLA-B*5101:requirement for all three p70 immunoglobulin domains. Eur J Immunol 27:568

    CAS  PubMed  Google Scholar 

  33. Ruiz-Cabello F, Garrido F (1998) HLA and cancer: from research to clinical impact. Immunol Today 19:539

    Article  CAS  PubMed  Google Scholar 

  34. Smyth MJ, Thia KYT, Street SEA, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191:661

    Article  CAS  PubMed  Google Scholar 

  35. Takeda K, Seki S, Ogasawara K, Anzai R, Hashimoto W, Sugiura K, Takahashi M, Satoh M, Kumagai K (1996) Liver NK1.1+ CD4+ αβ T cells activated by IL-12 as a major effector in inhibition of experimental tumour metastasis. J Immunol 156:3366

    CAS  PubMed  Google Scholar 

  36. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA (2000) NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1:515

    Article  CAS  PubMed  Google Scholar 

  37. Toneva M, Lepage V, Lafay G, Dulphy N, Busson M, Lester S, Vu-Trien A, Michaylova A, Naumova E, McCluskey J, Charron D (2001) Genomic diversity of natural killer cell receptors in three populations. Tissue Antigens 57:358

    Article  CAS  PubMed  Google Scholar 

  38. Uhrberg M, Valiante N, Shum B, Shilling G, Lienert-Weidenbach K, Corliss B, Tyan D, Lanier L, Parham P (1997) Human diversity in killer cell inhibitory receptor genes. Immunity 7:753

    Article  CAS  PubMed  Google Scholar 

  39. Van der Slik AR, Koeleman BPC, Verduijn W, Jan Bruining G, Roep BO, Giphart MJ (2003) KIR in type 1 diabetes: disparate distribution of activating an inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes 52:2639

    PubMed  Google Scholar 

  40. Wang Z, Margulies L, Hicklin DJ, Ferrone S (1996) Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression. Tissue Antigens 47:382

    CAS  PubMed  Google Scholar 

  41. Witt CS, Dewing C, Sayer DC, Uhrberg M, Parham P, Christiansen FT (1999) Population frequencies and putative haplotypes of the killer cell immunoglobulin-like receptor sequences and evidence for recombination. Transplantation 68:1784

    Article  CAS  PubMed  Google Scholar 

  42. Yen J-H, Moore BE, Nakajima T, Scholl D, Schaid DJ, Weyand CM, Goronzy JJ (2001) Major histocompatibility class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 193:1159

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by research grants from the ESTDAB project (No. QLRT-2000-01325) and from the Medical University, Sofia (No. 14/2002).

Author information

Authors and Affiliations

  1. Central Laboratory of Clinical Immunology, University Hospital Alexandrovska, 1, G. Sofiiski St., Sofia, 1431, Bulgaria

    Elissaveta Naumova, Anastassia Mihaylova, Milena Ivanova, Ludmila Quin & Miglena Toneva

  2. Department of Dermatology, National Center of Oncology, Sofia, Bulgaria

    Konstantin Stoitchkov

Authors
  1. Elissaveta Naumova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anastassia Mihaylova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Konstantin Stoitchkov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Milena Ivanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ludmila Quin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Miglena Toneva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elissaveta Naumova.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Naumova, E., Mihaylova, A., Stoitchkov, K. et al. Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals. Cancer Immunol Immunother 54, 172–178 (2005). https://doi.org/10.1007/s00262-004-0575-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-004-0575-z

Keywords

Search

Navigation